Engineering programmable enzymes for proteome editing

用于蛋白质组编辑的工程可编程酶

• 批准号: 10686522
• 负责人: Xin Zhou
• 金额: $ 160.2万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-01 至 2026-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10686522
• 关键词: Adopted; Antibodies; Antigens; Architecture; Basic Science; Binding; Biological; Biology; Biosensor; CRISPR/Cas technology; Cells; DNA; Development; Engineering; Enzyme Activation; Enzymes; Genetic; Genomics; Instruction; Label; Luciferases; Molecular; Molecular Conformation; Peptide Hydrolases; Phosphotransferases; Proteins; Proteome; Research; Signal Pathway; Signal Transduction; Specificity; Technology; Work; Writing; design; flexibility; genome editing; novel; protein degradation; protein function; response; synthetic enzyme

Project Summary/Abstract The development of CRISPR/Cas9 technology for genome editing and reprogramming was one of the most important discoveries in the past decade. The ability to deliver instructions to a specific DNA locus enables systematic interrogation of genetic functions in a broad range of species. In contrast to genomic research, our ability to manipulate the proteome, the functional components of a cell, lags far behind. Natural protein-modifying enzymes, such as proteases and kinases, generally lack the exquisite specificity to perform targeted activities directed to a particular protein. A strategy that enables user-controlled, target-dependent enzyme activation would enable new opportunities for interrogating, modulating, and harnessing endogenous protein functions. In this work, we design autoinhibited enzymes that are activated in response to a highly specific antigen- antibody interaction. These novel enzyme architectures are engineered to have a built-in capability to toggle between a target-unbound, enzyme-inactive conformation and a target-bound, enzyme-active conformation. We present a research plan that outlines the development of a target-activated protease, luciferase, and a kinase, and the subsequent application of the engineered enzymes for controlling protein degradation, constructing biosensors, and re-writing cell signaling pathways. These synthetic enzymes adopt regulatory mechanisms entirely different from the endogenous counterparts, enabling wide possibilities for both basic research and synthetic biological applications. 1

项目总结/摘要 用于基因组编辑和重编程的CRISPR/Cas9技术的发展是其中之一。 过去十年中最重要的发现。将指令传递到特定DNA位点的能力， 对广泛物种的遗传功能进行系统的研究。与基因组研究相比， 操纵蛋白质组（细胞的功能成分）的能力远远落后。天然蛋白质修饰 酶，如蛋白酶和激酶，通常缺乏执行靶向活性的精确特异性 针对特定的蛋白质。一种能够实现用户控制、目标依赖性酶激活的策略 将为询问，调节和利用内源性蛋白质功能提供新的机会。 在这项工作中，我们设计了一种自抑制酶，这种酶在对高度特异性抗原的反应中被激活- 抗体相互作用这些新的酶结构被设计成具有内在的切换能力， 在靶标未结合的酶失活构象和靶标结合的酶活性构象之间。我们 提出了一个研究计划，概述了目标激活蛋白酶，荧光素酶和激酶的发展， 以及工程化酶在控制蛋白质降解、构建 生物传感器和重写细胞信号通路。这些合成酶采用调节机制 完全不同于本土同行，为基础研究和 合成生物学应用。 1